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Type 2 diabeteste insulin when blood glucose levels are high. Dysfunction of this glucose-
stimulated insulin secretion (GSIS) is partly responsible for the manifestation of type 2 diabetes, a metabolic
disorder that is rapidly becoming a global pandemic. Mitochondria play a central role in GSIS by coupling
glucose oxidation to production of ATP, a signal that triggers a series of events that ultimately leads to insulin
release. Beta cells express a mitochondrial uncoupling protein, UCP2, which is rather surprising as activity of
such a protein is anticipated to lower the efﬁciency of oxidative phosphorylation, and hence to impair GSIS.
The mounting evidence demonstrating that insulin secretion is indeed blunted by UCP2 agrees with this
prediction, and has provoked the idea that UCP2 activity contributes to beta cell pathogenesis and
development of type 2 diabetes. Although this notion may be correct, the evolved function of UCP2 remains
unclear. With this paper we aim to provide a brief account of the present state of affairs in this ﬁeld, suggest a
physiological role for UCP2, and highlight some of our own recent results.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionPancreatic beta cells are important in the maintenance of blood
glucose homeostasis. When plasma glucose levels are high (N5 mM),
beta cells secrete insulin, which is a signal for peripheral tissues such as
skeletal muscle and liver to take up or store glucose, respectively.
Mitochondria play a pivotal role in glucose-stimulated insulin secretion
(GSIS): transported glucose is oxidised by beta cells, which leads to an
increased mitochondrial protonmotive force and cytoplasmic ATP/ADP
ratio, closure of ATP-sensitive potassium channels, depolarization of the
plasma membrane potential, opening of voltage-sensitive calcium
channels, inﬂux of calcium, and the eventual exocytosis of insulin-
containing granules ([1]; Fig. 1). In this canonical model of events, it is
important that mitochondrial electron transfer is coupled tightly to ATP
synthesis, as cytoplasmic ATP/ADP is the key GSIS signal. In addition to
the ‘triggering’ GSIS pathway shown in Fig. 1, beta cells exploit several
non-canonical ‘amplifying’pathways that facilitate optimal coordination
of insulin secretion in response to ﬂuctuating extra-cellular signals [2].
From a bioenergetic point of view, pancreatic beta cells are
interesting for several reasons. For example, the responsiveness of the
cytoplasmic ATP/ADP ratio in beta cells to glucose implies that this ratio
is controlled predominantly by ATP supply, which is fundamentally
different from the situation in most other cell types where ATP/ADP is
governedmainly by ATP demand [3]. This speciﬁc control distribution is
generally attributed to the particular hexokinase isozyme found in beta
cells, ‘glucokinase’ [4]. As a consequence of its high control over44 1223252805.
t).
l rights reserved.glycolysis, glucokinase is thought to control ATP/ADP and insulin
secretion almost exclusively [5]. Although the importance of this
glycolytic enzyme is evident from the control it exerts over blood
glucose homeostasis [4,6], this notion largely ignores the potential
constraints that are imposed on GSIS by mitochondrial metabolism [7].
One such constraint may be (in)efﬁcient oxidative phosphorylation. In
this respect, another interesting bioenergetic feature of beta cells is the
presence of a mitochondrial uncoupling protein, UCP2 [8]. The
expression of this protein in beta cells is rather paradoxical as one
would expect intuitively that UCP2 activity would uncouple mitochon-
drial substrate oxidation from ATP synthesis, and hence affect GSIS
unfavourably. A steadily increasing body of experimental evidence
indeed suggests that UCP2 impairs GSIS and as such is detrimental to
beta cell function. The question therefore arises as to why the beta cell
UCP2 has not landed on the evolutionary scrap heap. In other words,
how is UCP2 activity beneﬁcial to beta cell physiology?
The purpose of this paper is to provide a brief overview of research
on UCP2 in beta cells, which includes whole-animal studies as well as
experiments on isolated pancreatic islets and clonal beta cells. In this
respect, it should be noted that cultured and primary beta cells exhibit
different insulin secretion mechanisms. We put forward our thoughts
on the elusive physiological function of beta cell UCP2, but ﬁrst discuss
some of our own recent results that highlight the importance of
mitochondrial proton leak in general.
2. High proton leak in beta cells
As alluded to above, glucose-dependent ﬂuctuations in the mito-
chondrial protonmotive force and cytoplasmic ATP/ADP ratio are
Fig. 1. Canonical model of GSIS in pancreatic beta cells. Glucose is taken up by beta cells and catabolised glycolytically. The formed pyruvate is metabolised by mitochondria, which
leads to an increased mitochondrial protonmotive force (pmf) and rate of ATP synthesis. Consequently, the cytoplasmic ATP/ADP ratio rises, which causes closure of ATP-sensitive
potassium channels, depolarization of the plasma membrane potential, opening of voltage-sensitive calcium channels, inﬂux of calcium, and the eventual exocytosis of insulin-
containing granules. Beta cell mitochondria contain an uncoupling protein (UCP2) that dissipates the pmf as heat thus decreasing the efﬁciency of oxidative phosphorylation.
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regulatory feedback loops ensure these bioenergetic parameters are
relatively unresponsive to substrate supply [3]. A comparative
metabolic control analysis of oxidative phosphorylation in mitochon-
dria isolated from clonal beta cells (INS-1E) and rat skeletal muscle
revealed that this difference in ﬂexibility arises partly frommitochon-
drial peculiarities [9]. In particular, it appears that mitochondrial
proton leak exerts, in absolute terms, approximately 7.5 times stronger
control over ATP/ADP in INS-1E than muscle mitochondria (Fig. 2A).
Furthermore, the control of leak over membrane potential and
respiration is considerably higher in INS-1E than muscle mitochon-
dria, roughly 13 and 8 times in absolute terms, respectively. Based on a
comparative modular-kinetic analysis, we predicted that the relative
strength of beta cell leak is a direct consequence of its comparably
large magnitude: the contribution of leak to overall respiratory
activity is nearly 3-fold higher in mitochondria from INS-1E cells
than in those from rat skeletal muscle [9]. Similarly, the proton leak
activity exhibited by myoblast mitochondria is at least 5 times lower,
at all measured membrane potentials, than that observed in INS-1E
mitochondria [10]. These substantial differences are manifested at the
cellular level too, which demonstrates that they do not result from an
organelle-isolation artefact. When approximated as the intracellular
mitochondrial respiratory rate (i.e. myxothiazol-sensitive respiration)
that is resistant to oligomycin, it appeared that the leak was nearly 4-
fold higher in INS-1E cells than in myoblasts [10]. This difference is
reﬂected in the mitochondrial coupling efﬁciency (i.e. the proportion
of respiratory activity that is used to make ATP), which is about 25% in
INS-1E cells and 90% in myoblasts (Fig. 2B). This implies that the
fraction of INS-1E respiration used to drive ‘futile’ proton leak is
roughly 75%, which is high compared to the 20–30% observed
generally in other cells types [10].
Proton leak activity in isolated mitochondria is mainly constitutive
and depends largely on the amount (but not activity) of the adenine
nucleotide translocase [11]. This basal leak, however, is unlikely to
explain the observed leak difference between INS-1E cells and
myoblasts, since the adenine nucleotide translocase content is the
same in these systems (C. Affourtit and M. D. Brand, unpublished
observation). Some mitochondrial proton leak activity is inducible,
which allows modulation of the energy transduction coupling
efﬁciency [12]. This inducible proton conductance can be catalysed
by the adenine nucleotide translocase and by speciﬁc uncoupling
proteins. Because of its prominent presence in beta cells [8], it isconceivable that UCP2 accounts for the high leak activity observed in
INS-1E cells. Our RNA interference experiments to test this notion
directly are discussed below in relation to work reported by others.
3. UCP2 regulation
Expression of the Ucp2 gene is upregulated by several transcription
factors, including the sterol-regulatory-element-binding-protein-1c
[13] and the peroxisome-proliferator-activated receptors PPARα [14]
and PPARγ [15,16], as well as by the PPARγ coactivator PGC-1α [17,18].
Repression of the gene can be effected by Sirt1, a mammalian homo-
logue of the yeast silencing information regulator-2 [19]. Furthermore,
Ucp2 is a transcriptional target of Foxa1, one of the forkhead
transcription factors, which represses expression too, although it is
not understood at presentwhether this is a direct or indirect effect [20].
Various environmental factors modulate Ucp2 transcription: message
levels are increased when beta cells are exposed to cold [17], elevated
glucose or non-esteriﬁed fatty acid levels [15] and hydrogen peroxide
[21], whilst it is decreased upon exposure to interleukin-1ß [22]. Most
of this information on transcriptional regulation has been obtained
from research on rodents, but it is becoming clear that the principal
molecular mechanisms are similar in humans, despite a lack of
sequence homology within the regulatory region of the respective
genes [18].
It is important to realise that UCP2mRNA and protein levels are not
necessarily proportional in beta cells: a low in vivo protein content
contrasts for example with a high amount of message, and protein
increasesmay occurwithout changes inmRNA [23]. Such observations
suggest that some UCP2 regulation occurs at the translational level
[23], but could in principle also be explained bya high and variable rate
of protein degradation. In strong favour of translational regulation,
however, is the ﬁnding that a single-base substitution in the 3′ region
of an upstream open reading frame within the UCP2 mRNA alters
translation signiﬁcantly [24]. It is this open reading frame that is
indeed required for stimulation of UCP2 expression by glutamine [25],
an amino acid that has been implicated in insulin secretion [26].
Generally, UCP2 and UCP3 increase the proton conductance of
isolated mitochondria, but only when they are activated by super-
oxide, reactive oxygen species derivatives such as hydroxynonenal, or
by other reactive alkenals [27]. The activity of these relatively novel
carriers is inhibited by purine nucleoside di- and triphosphates [27],
similar to the activity of the archetypal uncoupling protein, UCP1 [28].
Fig. 2. High proton leak exerts relatively strong control over oxidative phosphorylation
in INS-1E cells. A: coefﬁcients quantifying control by proton leak over respiratory
activity, membrane potential (Δψ), and extra-mitochondrial ATP/ADP in INS-1E and rat
skeletal muscle mitochondria (orange and grey bars, respectively) were sampled from
data reported in [9]. B: the coupling efﬁciency of INS-1E cells and C2C12 myoblasts was
calculated from data reported in [10] as the percentage myxothiazol-sensitive (i.e.
mitochondrial) respiratory activity that was inhibited by oligomycin (n=4).
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stimulated considerably by superoxide in a GDP-sensitive manner
[29]. Moreover, removal of endogenous superoxide causes a time-
dependent increase in mitochondrial membrane potential in pan-
creatic islets from wild type but not Ucp2-ablated mice, which shows
that UCP2 activity is stimulated by superoxide [30]. Together, these
results demonstrate clearly that as well as the concentration, the
activity of UCP2 is subject to regulation in beta cells.
Itmaybe evident from this section that beta cell UCP2 is extensively
regulated at many levels ranging from gene transcription to catalysis.
One area of potential regulation that has not been explored in any
detail to date, is protein degradation. In this respect, it isworth noticing
that UCP2 protein in spleen, lung, and the duodenum is turned over
exceptionally rapidly, exhibiting a half-life of roughly 30 min [31]. In
INS-1E insulinoma cells, we ﬁnd a UCP2 half-life of the same order of
magnitude, approximately 60 min (V. Azzu, C. Affourtit, E. P. Breen, N.
Parker and M. D. Brand, submitted for publication).
4. UCP2 controls GSIS
Because UCP2 dissipates the mitochondrial protonmotive force as
heat (Fig. 1), it is intuitively likely that its activity in beta cells will
blunt the response of the cytoplasmic ATP/ADP ratio to glucose, andthus attenuate insulin secretion. Evidence to support the notion that
GSIS is indeed modulated by UCP2 is increasing steadily. Adenoviral
overexpression of UCP2 attenuates GSIS in pancreatic islets [32] and
cultured insulinoma cells [33]. Although overexpression of UCPs is
generally prone to ‘false positives’ – because misfolded protein will
increase proton conductance non-speciﬁcally [27] – these results
underpin the principal idea that GSIS is impaired when oxidative
phosphorylation is uncoupled. Studies involving Ucp2-ablated mice
have shown more convincingly that UCP2 attenuates GSIS under
conditions of (patho)physiological relevance [8,30,34,35]. In pancrea-
tic islets from Ucp2-knockout mice, ATP levels are higher than control
islets, and GSIS is increased [8]. Inwild type islets, fat feeding and fatty
acids lower glucose-induced increases in mitochondrial membrane
potential, reactive oxygen species (ROS) production, cytosolic ATP/
ADP and calcium, and insulin release. These attenuating effects of fatty
acids are abolished in Ucp2-knockouts, which demonstrates they are
mediated by this carrier [34,35]. Furthermore, GSIS is enhanced when
endogenous superoxide is diminished by a superoxide dismutase
mimetic, and impaired during hyperglycaemia through a mechanism
involving superoxide. Both these observations are exclusive to wild
type islets, again supporting a signal-mediating role for UCP2 [30].
In general, the interpretation of experiments involving Ucp2-knock-
out animals couldbe complicatedbypotentiallycomplexdevelopmental
adaptations to the life-long absence of the Ucp2 gene. Additionally, the
observed changes in islet behaviour may have in part resulted from the
absence of UCP2 in other tissues such as the brain. Of importance in this
respect is the recently reported work on glucose-excitable pro-
opiomelanocortin neurons that are found in the arcuate nucleus of the
hypothalamus [36]. Glucose-sensing by these neurons was shown to
play a role in the maintenance of blood glucose homeostasis, and to be
regulated negatively by UCP2 [36]. These results illustrate nicely that
beta cell behaviour may well be affected by distal UCP2 effects.
To testwhether or not the high proton leak activity exhibitedby INS-
1E cells [10] is accounted for by UCP2, we followed an RNA interference
approach to reduce its level by over 80%, and then measured
consequent effects on respiration and GSIS. UCP2 knockdown lowered
the intracellularmitochondrial respiratory activity thatwas resistant to
oligomycin by approximately 30% [10]. Sincewe estimated that roughly
75% of INS-1E respiration is used to drive proton leak, this number
suggests that UCP2 is responsible for about 20% (i.e. 0.3×0.75) of the
resting respiratory activity. As a result, UCP2 knockdown signiﬁcantly
increases the efﬁciency bywhich INS-1E cells couple respiration to ATP
synthesis (Fig. 3A). The drop in UCP2 protein did not appear to affect
insulin secretion at 2 mM glucose, but increased it considerably at
30 mM (Fig. 3B). KCl-induced insulin release, which does not rely on
mitochondrial metabolism, was not affected by UCP2 knockdown.
These observations are in qualitative agreement with the results
obtained from experiments with Ucp2-ablated mice, and demonstrate
that GSIS is improved upon acute removal of UCP2.
Acute pharmacological interference with UCP2 activity also affects
beta cell physiology. The aforementioned UCP2-mediated effect of
endogenous superoxide scavenging on mitochondrial membrane
potential and GSIS is a good example of such immediate control by
UCP2 [30]. Additional support for acute UCP2 effects on islet behaviour
comes from studies with genipin, a cell-permeant compound that is
reported to inhibit UCP2-mediated proton leak in isolated kidney
mitochondria [37]. In pancreatic islets from wild type but not Ucp2-
knockout mice, genipin increases the mitochondrial membrane
potential and cytosolic ATP, closes KATP channels, and stimulates
insulin secretion [37]. Analogously, inhibition of UCP2 by genipin
results in immediate excitation of pro-opiomelanocortin neurons [36].
5. Involvement of UCP2 in type 2 diabetes
Type 2 diabetes is a common metabolic disorder that is reaching
pandemic proportions [38]. The disease is polygenic, inﬂuenced strongly
Fig. 3.UCP2 knockdown increases coupling efﬁciency and enhances GSIS. These data are
an expansion of results reported in [10] and were obtained from experiments with INS-
1E cells transfectedwith scrambled (grey bars) or UCP2 siRNA (orange bars). A: coupling
efﬁciencies (cf. Fig. 2B) are means±S.E.M. of twelve (scrambled siRNA) and twenty-two
(pooled siRNAs targeted at three separate Ucp2 exons) experiments. B: insulin secretion
was measured at 2 and 30 mM glucose (G2 and G30) and 2 mM glucose+30 mM KCl
(KCl). Data are means±S.E.M. of nine (G2 and G30) and ﬁfteen (KCl) experiments with
each condition assayed four to eight times.
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defects in the function of both peripheral tissues and pancreatic beta
cells. Beta cell dysfunction is widely believed to be secondary to
prolonged exposure to high glucose and lipid levels [39,40], conditions
that are often associated with obesity and insulin-resistance. Although
the mechanism of beta cell glucotoxicity and lipotoxicity is not fully
understood, reactive oxygen species are likely to be involved [41,42], as
such species are increased during both hyperglycaemia [30,43] and
hyperlipidaemia [35,44,45]. Superoxide production is increased accord-
ingly in diabetic animal models [30,43]. Interestingly, the presence and
activity of UCP2 appear to correlate rather closely with these
phenomena. UCP2 expression is upregulated by high glucose [15,30]
and fattyacid [15,32,34,46] levels, and is relatively high inmousemodels
of type 2 diabetes [8,47–49] and lipotoxicity [50,51]. In addition, UCP2
activity is stimulated by superoxide [30]. From these observations, the
idea has emerged that UCP2 plays an important role in beta cell
pathology and the development of type 2 diabetes [38,52–55].
The putative involvement of UCP2 in the aetiology of type 2
diabetes is supported by experiments that show ablation of UCP2
activity rescues the impaired beta cell function of various diabetic
mouse models. For example, leptin-deﬁcient ob/ob mice exhibit
obesity-induced diabetic symptoms that are ameliorated upon cross-
breeding with Ucp2-ablated animals: ﬁrst-phase insulin secretion is
restored, serum insulin levels are increased,whilst blood glucose levels
are greatly decreased [8,30]. Type 2 diabetes can also be modelled by
subjecting pancreatic islets chronically to high glucose levels or byfeeding mice a high-fat diet. The impaired GSIS that results from such
treatments is greatly diminished in Ucp2 knockout mice ([30] and
[34,35], respectively). Similarly, beta cell dysfunction caused by
hyperglycaemia or leptin-deﬁciency is reversed acutely upon pharma-
cological UCP2 inhibition bygenipin [37]. Acute knockdownofUCP2by
RNAi partially restoresGSIS in a beta cell lipotoxicitymousemodel that
overexpresses the sterol-regulatory-element-binding-protein-1c [51].
In ob/ob mice, short-term RNAi-mediated UCP2 knockdown does not
improve GSIS, which seems discrepant with the Ucp2 knockout data,
although GSIS is enhanced in wild type control animals [49]. In a
different study, however, the hyperglycaemic syndrome exhibited by
ob/ob mice was improved by administration of Ucp2 antisense
oligonucleotides [56]. Thismetabolic beneﬁt, whichwas also observed
inmice rendered diabetic throughhigh-fat feeding, appears not only to
be due to increased insulin secretion by beta cells, but also to enhanced
insulin action onperipheral tissues [56]. In this respect, it is interesting
to note that pro-opiomelanocortin neurons lose their ability to sense
glucose as a result of a high-fat diet, and that this loss is restored by
acute UCP2 inhibition, or prevented by genetic Ucp2-ablation [36].
The corroborative evidence for the suggested role of UCP2 in beta cell
pathogenesis is extensive. It may nonetheless be clear that the evolved
function of UCP2 is unlikely to be pathological. From an evolutionary
perspective, UCP2 activity in beta cells must have a physiological out-
come that is beneﬁcial to the organism under certain conditions.
6. The elusive physiological role of UCP2
Regarding the physiological relevance of novelmitochondrial UCPs,
it has been proposed that they have an ancestral function of protection
against superoxide production and consequent damage [57,58]. This
‘mild uncoupling’ hypothesis is based on the observations that matrix
superoxide production from complex I exhibits a steep dependence on
the protonmotive force, and that matrix superoxide stimulates UCP-
mediated proton conductance. Activation of UCPs thus provides a
negative feedback loop attenuating further superoxide production, at
the expense of a slightly lowered energy transduction efﬁciency. It is
predicted by this model that UCP-speciﬁc mild uncoupling occurs
under conditions that allow endogenous superoxide production and,
conversely, that impaired UCP activity increases the mitochondrial
membrane potential, ROS production, and oxidative damage. In
pancreatic islets, Ucp2-ablation increases the membrane potential as
well as superoxide production; the effect of genetic knockout on
membrane potential is mimicked by conditions under which super-
oxide levels are lowered with a cell-permeant superoxide dismutase
mimetic [30]. These results are consistent with the notion that UCP2
performs a protective task against oxidative damage in beta cells. In
this scenario, UCP2-mediated beta cell dysfunction and development
of type 2 diabetes are pathological side effects of a damage limitation
mechanism that is induced during prolonged periods of hyperglycae-
mia and hyperlipidaemia. A defensive role of UCP2 against ROSmay be
necessitated by the striking lack of expression and activity of
antioxidant enzymes in beta cells [59–61]. However, such a function
does not agree with observations that Ucp2 knockout mice exhibit
improved glucose homeostasis for an extended period of time and do
not suffer beta cell loss, despite having elevated ROS levels [30].
The intrinsically low antioxidant levels in beta cells may facilitate a
role for ROS in cell signalling. It is becoming increasingly clear in this
respect that physiological, non-damaging ROS levels are important in
apoptosis, kinase activation, immune response, calcium signalling and
gene expression (listed in [62]). It seems therefore reasonable to
postulate that ROS are involved in the regulation of beta cell physiology
[63]. For example, a ﬂuctuating superoxide level could modulate UCP2
activity, and thereby provide a signal that could be relevant under both
pathological andphysiological conditions.Our recent results concerning
the relatively high contribution of UCP2 to INS-1E respiration, its atten-
uating effect on GSIS ([10]; cf. Fig. 3), and the signiﬁcant control exerted
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consistent with this role. We suggest that the relatively high leak
exhibited by beta cells (Fig. 2B) ampliﬁes the effect of physiological
regulators of UCP2 proton conductance (i.e. superoxide) on theATP/ADP
ratio and hence on GSIS.
UCP2 activity may be important to coordinate the physiological
response of beta cells to ﬂuctuating nutrient supply. A signalling role of
UCP2 could be important to restrict insulin secretion when blood
glucose levels are low, for example during sleep (Fig. 4A). The circu-
lation of non-esteriﬁed fatty acids is increased under such conditions,
which will cause both UCP2 expression [15] and activation by
superoxide [30] that is formed upon fatty acid oxidation [45,64].
Despite the availability of an adequate substrate for ATP production,
insulin secretion will consequently decrease, which prevents the
occurrence of hypoglycaemia in a fasting state [55,57]. After a meal,
on the other hand, blood glucose and lipid concentrations will rise
considerably, again causing expression [15] and superoxide activation
of UCP2 [30,45]. Under these conditions, insulin release needs to be
increased markedly. Such an increase will indeed happen as an
immediate, triggering response to the elevated glucose level, although
it may not be as pronounced as intuitively expected because of
seemingly undesirable UCP2 activity. However, to sustain a boosted
insulin secretion rate for as long as it may take to deal appropriately
with the postprandial nutrient load, signals additional to an increased
ATP/ADP are required to amplify the initial GSIS [2,65]. These
potentiating signals may include NADPH, acetyl-CoA, malonyl-CoA,
and α-ketoglutarate, the production of which depends on TCA cycle
activity [66]. When substrate supply is high, turnover of this cycle is
likely to be limited by the mitochondrial protonmotive force. UCP2
activity may be important during periods of nutrient abundance to
alleviate this backpressure and thus allow TCA cycle turnover to occur
uncoupled from ATP synthesis (Fig. 4B). In this view of events, GSIS is
sustained at the expense of blunted ﬁrst-phase insulin secretion. The
degree of this initial attenuation is not anticipated to be high, however,
since nutrient-induced UCP2 expression and subsequent activation are
likely to be slower events than ﬁrst-phase GSIS, which lasts only a fewFig. 4. Putative involvement of UCP2 in coordinating the response of beta cells to physiologica
circulation of non-esteriﬁed fatty acids (NEFA) rises. These free fatty acids increase UCP2 e
indirectly by superoxide that is formed during beta oxidation. The mitochondrial protonmot
insulin secretion (blue route) attenuated, which protects against hypoglycaemia. After a meal
these conditions would facilitate increased and sustained GSIS (green and blue routes) bec
though the pmf is high in the abundant presence of nutrients.min [2]. This potential role of UCP2 to facilitate unrestricted electron
transfer for metabolic purposes (i.e. to produce GSIS ampliﬁers) is not
without precedent, as the plant UCP performs a similar function,
allowing mitochondrial metabolism when required during photore-
spiration in Arabidopsis thaliana [67].
If the exclusive physiological role of UCP2 in beta cells is indeed to
lowerGSIS during periods of fasting and, conversely, to allow sustained
GSIS when nutrients levels are high, then its activity would need to be
dampened rather promptly under intermediate conditions, i.e.
between meals. This may be achieved by virtue of the exceptionally
short half-life of UCP2 [31] that would ensure rapid protein degrada-
tion when glucose and lipid concentrations have reattained their
resting level, and hence de novo UCP2 synthesis has stopped. UCP2
levels and activity would thus correlate with physiologically relevant
nutrient ﬂuctuations. In this functional model, the chronic exposure to
hyperglycaemia and hyperlipidaemia that eventually leads to beta cell
dysfunction may be explained by the persistent nature of the UCP2-
mediated drop in ATP/ADP under pathological conditions, and perhaps
also by a gradual deterioration of GSIS-amplifying mechanisms. The
pronounced beneﬁcial effect of Ucp2-ablation on glucose homeostasis
in diabetic animalmodels is likely to be a combined effect of enhanced
ﬁrst-phase insulin secretion [8], increased insulin action on peripheral
tissues [56], and improved behaviour of glucose-sensing neurons [36].
7. Concluding remarks
The evidence for a GSIS-regulatory role of UCP2 is extensive and
convincing, which demonstrates that the efﬁciency of mitochondrial
energymetabolismexerts signiﬁcant control overGSIS, andweakens the
notion that insulin secretion is controlled exclusively by glucokinase.
Involvement of UCP2 in beta cell pathogenesis and type 2 diabetes is
underpinned by strong experimental support, whereas its physiological
role remains speculative. We think it would be sensible to establish the
evolved function of UCP2 in beta cells, if this carrier is to fulﬁl its promise
as a safe therapeutic target in the treatment or prevention of type 2
diabetes. In this respect, it is clear that our functional model requiresl ﬂuctuations in nutrient supply. In the fasting state (A) blood glucose levels are low and
xpression and stimulate its activity either directly (e.g. by nucleotide displacement) or
ive force (pmf) that results from NEFA oxidation is consequently blunted and canonical
(B) glucose and NEFA levels are high, which requires insulin release. UCP2 activity under
ause UCP2 allows continued production of TCA cycle-derived amplifying signals even
978 C. Affourtit, M.D. Brand / Biochimica et Biophysica Acta 1777 (2008) 973–979rigorousexperimental testing,which should revealwhetherornotUCP2
regulates insulin secretion in response to physiologically relevant
ﬂuctuations in nutrient supply.
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